Related to Celera Gets CE Mark for KIF6 Genetic Test for Coronary Heart Disease Risk

• Exact Sciences Closes $8.2M Placement and Inks Deal with Mayo Clinic
  
• Axis-Shield Acquires Rights to Develop Sepsis Diagnostic from Hansa Medical
  
• Swiss Viollier to Launch Colorectal Cancer Blood Test in Europe
  
• Israeli Government Boosts Compugen Drug Discovery Funding with $400K
  
• Castle Biosciences Chooses Phoenix Hospital to Offer Its Molecular Diagnostic for Brain Cancer
  
• EU Sanctions Novartis Drug for Steroid-Induced Osteoporosis
  
• Celera Licenses Five Cancer-Related Targets to Bayer Schering Pharma
  
• Spinreact to Include AbD Serotec Antibodies in Clinical Diagnostic Kits
  
• Cepheid Gains FDA Approval for C. Difficile Molecular Diagnostic
  
• Debiopharm’s Sexual Deviation Treatment Gets Swiss Approval
  
• Axial Biotech Selects University of Utah Database to Develop Personalized Tests for Spine Disorders
  
• Nycomed’s Intranasal Fentanyl Drug Gains European Approval for Breakthrough Cancer Pain
  
• Cryopraxis to Assess Cryo-Cell's Menstrual Stem Cell Technology for Diagnosing Endometriosis
  
• QuantRx Creates Joint Venture with NuRx Focused on Point-of-Care Products
  
• Otsuka’s Vasopressin Agonist Approved in Europe for Hyponatremia
  
• MP Biomedicals to Develop Alzheimer’s Blood Test Based on UCLA Technology
  
• Novartis’ Afinitor Receives EU Sanction for Advanced RCC After Failed Anti-VEGF Therapy
  
• Rosetta Genomics Taps Warnex as Canadian Distributor for Cancer Diagnostics
  
• Arup Taps Epigenomics’ mSEPT9 Biomarker to Develop Colorectal Cancer Test
  
• EMEA Issues Treatment Recommendations to Preserve Supply of Genzyme’s Gaucher’s Drug